Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Nov;48(10):1117-1127.
doi: 10.1111/apt.14990. Epub 2018 Oct 17.

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

Mona Munteanu  1   2   3 , Raluca Pais  2   3 , Valentina Peta  1 , Olivier Deckmyn  1 , Joseph Moussalli  2 , Yen Ngo  1 , Marika Rudler  2 , Pascal Lebray  2 , Frederic Charlotte  2 , Vincent Thibault  2 , Olivier Lucidarme  2   3 , An Ngo  2   3 , Françoise Imbert-Bismut  2 , Chantal Housset  3 , Dominique Thabut  2   3 , Vlad Ratziu  2   3 , Thierry Poynard  2   3 ; FibroFrance Group
Affiliations
Comparative Study

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

Mona Munteanu et al. Aliment Pharmacol Ther. 2018 Nov.

Abstract

Background: Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the prediction of liver-related death.

Aim: To validate the 10-year prognostic value of FibroTest in NAFLD for the prediction of liver-related death.

Method: Patients in the prospective FibroFrance cohort who underwent a FibroTest between 1997 and 2012 were pre-included. Mortality status was obtained from physicians, hospitals or the national register. Survival analyses were based on univariate (Kaplan-Meier, log rank, AUROC) and multivariate Cox risk ratio taking into account age, sex and response to anti-viral treatment as covariates. The comparator was the performance of the FibroTest in CHC, the most validated population.

Results: 7082 patients were included; 1079, 3449, 2051, and 503 with NAFLD, CHC, CHB, and ALD, respectively. Median (range) follow-up was 6.0 years (0.1-19.3). Ten year survival (95% CI) without liver-related death in patients with NAFLD was 0.956 (0.940-0.971; 38 events) and 0.832 (0.818-0.847; 226 events; P = 0.004) in CHC. The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with NAFLD was 0.941 (0.905-0.978)/1638 (342-7839) and even higher than in patients with CHC 0.875 (0.849-0.901; P = 0.01)/2657 (993-6586).

Conclusions: The FibroTest has a high prognostic value in NAFLD for the prediction of liver-related death. (ClinicalTrials.gov number, NCT01927133).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow sheet of population subsets
Figure 2
Figure 2
Survivals. All survivals were unadjusted Kaplan‐Meier curves. A, 10‐year‐overall survival was 0.824 (0.813‐0.835) among the 7082 included patients. B, 10‐year‐overall survival in NAFLD was 0.689 (0.647‐0.730), lower than 0.832 (0.818‐0.847) in CHC, and 0.891 (0.891‐0.922) in CHB, but much higher than in ALD 0.408 (0.345‐0.472). All P < 0.001. C, 10 year‐liver‐related survival was, in NAFLD 0.956 (0.940‐0.971), higher than 0.921 (0.910‐0.932; P = 0.004) in CHC, slightly lower than 0.969 (0.960‐0.979; P = 0.04) in CHB, but much greater than in ALD 0.585 (0.515 0.655; P < 0.001).
Figure 3
Figure 3
Overall survivals according to presence or absence of cirrhosis at baseline. Patients with NAFLD had lower survivals whatever the absence or presence of cirrhosis. A, Patients without cirrhosis at baseline. B, Patients with cirrhosis at baseline
Figure 4
Figure 4
Prognostic performances (AUROCs) of FibroTest. AUROC of FibroTest 0.941 (0.905‐0.978) (mean; 95% CI) purple line, for the prediction of 10 year‐liver‐related survivals in 1079 patients with NAFLD was significantly higher than in 2051 CHC 0.875 (0.849‐0.901; P = 0.01) green line, and not different than in 2051 CHB 0.848 (0.723‐0.974; P = 0.09) blue line, and then in 503 ALD, 0.695 (0.575‐0.816; P = 0.06) red line
See this image and copyright information in PMC

Comment in

References

    1. Munteanu M, Tiniakos D, Anstee Q, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877‐889. - PMC - PubMed
    1. Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta‐analysis of individual patient data. PLoS ONE. 2012;7:e30325. - PMC - PubMed
    1. Imbert‐Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069‐1075. - PubMed
    1. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158:807‐820. - PubMed
    1. Houot M, Ngo Y, Munteanu M, et al. Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 2016;43:16‐29. - PMC - PubMed

Publication types

MeSH terms

Associated data